Glucagon-like peptide-1 (GLP-1) is a 30- or 31-amino-acid-long peptide hormone deriving from tissue-specific posttranslational processing of the proglucagon peptide.
Research in context. Evidence before this study Prior systematic reviews and meta-analyses have documented the effects of diverse pharmacological treatments for obesity on weight loss, cardiometabolic risk factors, and adverse effects. The most efficacious class of pharmacological treatments are the GLP-1 agonists or analogs. However, the relative efficacy of the latter agents remains unclear ...
Real users give insights on taking GLP-1 medications for weight loss, from the benefits to side effects.
In this systematic review and network meta-analysis, direct and indirect evidence from 64 RCTs in 27,018 patients with obesity or overweight was appraised and synthesized to compare the associations of each GLP-1 agonist or analog with relative weight loss and adverse events.
The US Food and Drug Administration (FDA) approval of multiple glucagon-like peptide-1 (GLP-1) receptor agonists for weight management has ushered in a new chapter for obesity care. Featuring diverse mechanisms of action, these drugs offer more effective solutions for long-term obesity management even as additional data on their long-term use is slowly being uncovered. Several randomized ...
Obesity is a chronic disease requiring chronic management. Anti-obesity medication for the treatment of obesity includes the glucagon-like peptide-1 (GLP-1) agonists liraglutide and semaglutide. This review will discuss the results of weight loss clinical trials for these agents, in addition to anorectic gut hormone analogue combinations and co-agonist drugs targeting gut hormone receptors, as ...
recent review of existing studies explains how GLP-1 analogue drugs, such as semaglutide, work to suppress appetite and aid weight loss.
Liraglutide, a long-acting cardioprotective glucagon-like peptide (GLP)-1 analog, is effective for medical weight loss and glycemic control in type 2 diabetes. It is generally well tolerated with mild side effects. There are few reports on complications from Liraglutide overdose.
Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials. Diabetes Care.
